公开(公告)号：US20170152313A1

公开(公告)日：2017-06-01

申请号：US15346026

申请日：2016-11-08

Applicant: NOVARTIS AG

Inventor： Kurt Alex HELDWEIN ,  Igor SPLAWSKI ,  Jennifer BROGDON ,  Joshua GOLDSTEIN ,  William DOLE ,  John TRAUGER ,  Chonghui ZHANG

IPC: C07K16/28 ,  A61K45/06 ,  A61K9/00 ,  A61K39/395

CPC classification number: C07K16/28 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07K14/4726 ,  C07K16/2851 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20190040128A1

公开(公告)日：2019-02-07

申请号：US15971250

申请日：2018-05-04

Applicant: NOVARTIS AG

Inventor： Kurt Alex HELDWEIN ,  Igor SPLAWSKI ,  Jennifer BROGDON ,  Joshua GOLDSTEIN ,  William DOLE ,  John TRAUGER ,  Chonghui ZHANG

IPC: C07K16/28 ,  A61P9/08 ,  A61P9/12 ,  A61P9/04 ,  A61K9/00 ,  A61K39/395 ,  A61K45/06 ,  A61P9/10 ,  A61K39/00 ,  C07K14/47

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.